52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC).
Saved in:
| Title: | 52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC). |
|---|---|
| Authors: | Vogel, A.1 (AUTHOR), Boeck, S.2 (AUTHOR), Waidmann, O.3 (AUTHOR), Bitzer, M.4 (AUTHOR), Wenzel, P.5 (AUTHOR), Belle, S.6 (AUTHOR), Springfeld, C.7 (AUTHOR), Schulze, K.8 (AUTHOR), Weinmann, A.9 (AUTHOR), Lindig, U.10 (AUTHOR), Trautwein, C.11 (AUTHOR), Dechow, T.12 (AUTHOR), Lammert, F.13 (AUTHOR), Plentz, R.14 (AUTHOR), Koehne, C-H.15 (AUTHOR), Kunzmann, V.16 (AUTHOR), Maenz, M.17 (AUTHOR), Kirstein, M.M.18 (AUTHOR), Saborowski, A.19 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS563-S563. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.080 |
